Actavis to buy Durata in a deal valued at about $675 mln | Business Information & News | Westlaw

Actavis to buy Durata in a deal valued at about $675 mln | Business Information & News | Westlaw

View on Westlaw or start a FREE TRIAL today, Actavis to buy Durata in a deal valued at about $675 mln, Business Information & News
10/6/14 REUTERS 20:36:45
REUTERS
Copyright © 2014 Thomson Reuters
October 6, 2014
Actavis to buy Durata in a deal valued at about $675 mln
Ankur Banerjee
(Reuters) - Generic drugmaker Actavis Plc said it would acquire Durata Therapeutics Inc in a deal valued at about $675 million to bolster its infectious disease portfolio.
Durata's shares were trading up 77 percent at $24.55 premarket, above Actavis'...
---- Index References ----
Company: TEVA PHARMACEUTICAL INDUSTRIES LTD; SALIX PHARMACEUTICALS LTD; DURATA THERAPEUTICS INC; MYLAN INC; ACTAVIS INC; DEBEVOISE AND PLIMPTON LLP; MERRILL LYNCH AND CO INC
Industry: (Drug Approval Process (1DR91); Drug Discovery & Development Process (1DR41); Pharmaceuticals Research & Development (1PH57); Pharmaceuticals (1PH33); Pharmaceuticals & Biotechnology Industry Highlights (1PH07); Pharmaceuticals & Biotechnology (1PH13); Generic Drugs (1GE93))
Region: (Northern Europe (1NO01); Europe (1EU83); Western Europe (1WE41); Iceland (1IC78))
Language: EN
Other Indexing: (Dorr LLP) (Wilmer Cutler Pickering Hale)
Keywords: securities; ma (MCC:OEC); (N2:US); (N2:AMERS); (N2:USA); (MCCL:OVR); (MCCL:OEC)
Word Count: 251
End of Document© 2023 Thomson Reuters. No claim to original U.S. Government Works.